Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease small-cell lung cancer (LD-SCLC): TORG 0604

Table 3 Worst grade of adverse events observed during chemotherapy and TRT at phase II

	During phase II chemotherapy				During TRT
n = 35	Grade (NCI-CTC ver. 2.0)
Toxicity	1–2	3	4	3+4 (%)	1–2	3	4	3+4 (%)
Leukocytes	27	3	2	14.3	14	0	0	0
Neutrophils	13	14	4	51	10	3	0	8.4
Hemoglobin	20	11	2	37.1	21	3	0	8.4
Platelets	24	2	2	11.4	4	1	0	2.8
Hyponatremia	1	2	1	8.6	1	1	0	2.8
AST/ALT	12	1	0	2.8	5	0	0	0
Fatigue	18	0	0	0	6	0	0	0
Anorexia	21	5	0	14.3	6	0	0	0
Nausea/Vomiting	21	1	0	2.8	2	0	0	0
Skin rash	2	0	0	0	5	0	0	0
Esophagitis	0	0	0	0	12	0	0	0
Diarrhea	18	0	0	0	3	0	0	0
Stomatitis	0	1	0	2.8	3	1	0	2.8
Alopecia	14	0	0	0	10	0	0	0
Infection	1	0	0	0	0	0	0	0
FN		2	0	5.7		0	0	0
Pheumonitis	0	1	0	5.7	4	2	0	5.7

TRTThoracic Radiotherapy
NCI-CTC National Cancer Institute - Common Toxicity Criteria
AST Aspartate transaminase, ALT Alanine transaminase, FN Febrile Neutropenia

ISSN: 1471-2407